processing...

Choose a analysis:

Hint: You can either select all, or use ctrl + select to choose multiple

Check the experimental factors of this study in the table below. The first column is grouped (combined) factors and subsequent columns are individual factors

sample_sourcecombined_factorsSource_Name[gating]TreatmentBatchNote
1Bone marrowSource_Name[gating]:Bone marrow supernatant | Treatment:5 FU 2 weeks | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D)Source_Name[gating]:Bone marrow supernatant5 FU 2 weeks1cUnlabeled AAs were used for total AA (FigS2.D)
2Bone marrowSource_Name[gating]:Bone marrow supernatant | Treatment:HSC Basal | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D)Source_Name[gating]:Bone marrow supernatantHSC Basal1cUnlabeled AAs were used for total AA (FigS2.D)
3Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h1c[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).
4Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
5Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
6Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
7Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h1c[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K).
8Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
9Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
10Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D).
11Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).
12Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).
13Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h1b[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).
14Bone marrowSource_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).Source_Name[gating]:Lin<U+2013> Scal1+ c-Kit+ CD48<U+2013> CD150+ (HSC)HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h1c[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).

Choose factor column:

Take a hint from the table above




  logo